While aAb against a variety of GPCR including the endothelin type A receptor and angiotensin II receptor type 2 have been identified in a wide range of cardiovascular diseases where they have been proposed to contribute critically to disease initiation and/or progression, aAb against S1PR have so far only been reported in a single case report. Here, EDNRA is linked to cardiovascular disorder.